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SF and p97 are ATPases required for the heterotypic
fusion of transport vesicles with their target mem-
branes and the homotypic fusion of organelles. NSF
uses ATP hydrolysis to dissociate NSF/SNAPs/SNAREs
complexes, separating the v- and t-SNAREs, which are
then primed for subsequent rounds of fusion. In contrast,
p97 does not dissociate the p97/p47/SNARE complex even
N
 
in the presence of ATP. Now we have identiﬁed a novel
essential factor for p97/p47-mediated membrane fusion,
named VCIP135 (valosin-containing protein [VCP][p97]/p47
complex-interacting protein, p135), and show that it binds
to the p97/p47/syntaxin5 complex and dissociates it via
p97 catalyzed ATP hydrolysis. In living cells, VCIP135 and
p47 are shown to function in Golgi and ER assembly.
 
Introduction
 
The Golgi apparatus plays a central role in intracellular
membrane traffic. It undergoes dramatic transformation
during the cell cycle (Warren, 1993). During mitosis, it is
fragmented into thousands of vesicles and short tubules that
are dispersed throughout the cytoplasm. Some or all of
them might be absorbed into ER, which is still a matter of
controversy (Zaal et al., 1999; Jokitalo et al., 2001; Check,
2002). At telophase, the mother cell divides into two
daughter cells, and a Golgi apparatus is rapidly reassembled
from fragments within each daughter cell (Lucocq et al.,
1989). Experiments using an in vitro Golgi reassembly assay
showed that reassembly from membrane fragments requires
at least two ATPases: NSF and p97 (also known as valosin-
containing protein [VCP]*) (Rabouille et al., 1995b). The
mechanism of action of NSF in mediating membrane fusion
has been the subject of a considerable amount of work, and
its role has been well characterized. In contrast to NSF,
much less is known about the mechanism of action of p97.
Only one cofactor has so far been identified, namely p47. It
forms a tight complex with p97, which is essential for the in
vitro Golgi reassembly (Kondo et al., 1997). The SNARE
protein, syntaxin5, is a receptor in Golgi membranes for the
p97/p47 complex with p47 mediating the binding of p97
to syntaxin5 (Rabouille et al., 1998).
NSF binds to SNAREs via 
 
 
 
-SNAP and dissociates
the resulting complex using ATP hydrolysis (Sollner et
al., 1993). The SNAREs are thought to be activated
(“primed”) in the process of the complex dissociation
(Wickner and Haas, 2000). These primed SNAREs are
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then available to pair with SNAREs in other membranes,
thereby inducing further rounds of fusion. Similar to NSF,
p97 is also thought to prime SNAREs via ATP hydrolysis,
though in this instance only t-SNAREs appear to be in-
volved and the mechanism of priming is unclear. In previ-
ously reported experiments, we isolated a p97/p47/syn-
taxin5 complex and visualized it by EM (Rabouille et al.,
1998). Surprisingly, this complex was observed even in the
presence of ATP. Unlike NSF, p97 appears not to dissoci-
ate the p97/p47/syntaxin5 complex. Therefore, how does
the p97/p47 complex prime SNAREs? Is another unidenti-
fied factor required for the dissociation of the p97/p47/
SNARE complex?
Another important question with respect to p97 and its
yeast homologue, Cdc48p, is whether it is really necessary
for membrane fusion in vivo. Several groups have reported
on its membrane fusion activity in different in vitro assay
systems (Acharya et al., 1995; Latterich et al., 1995;
Rabouille et al., 1995b; Roy et al., 2000; Hetzer et al.,
2001), but there is no direct evidence concerning its in vivo
function. In addition, several functions of p97/Cdc48p in
other biological pathways have been reported apart from its
action in membrane fusion (Patel and Latterich, 1998;
Meyer et al., 2000; Dai and Li, 2001; Ye et al., 2001;
Jarosch et al., 2002), and the lack of evidence about its
membrane fusion activity in vivo has caused much confu-
sion and controversy.
In this paper, we have resolved some of these arguments.
We identified VCIP135 (VCP[p97]/p47 complex-interact-
ing protein, p135), a novel essential factor for p97/p47-
mediated membrane fusion and showed that it binds to the
p97/p47/syntaxin5 complex and dissociates it via p97 cata-
lyzed ATP hydrolysis. In addition, by microinjection of anti-
bodies to VCIP135 and p47 into living cells we have suc-
ceeded in clarifying that VCIP135 and p47 are required for
Golgi assembly and ER network formation in vivo.
 
Results
 
Two binding interactions in the p97/p47 complex
 
To determine the p97-binding sites on p47, we prepared
several GST-tagged deletion mutants of p47 and checked
their ability to bind to p97 (Fig. 1 A). p47(171–270) and
p47(271–370) bind to p97, but p47(1–170) does not,
suggesting the existence of two p97-binding sites on p47.
This was confirmed by competition experiments between
full-length p47 (p47full) and p47 fragments (Fig. 1 B).
p47(171–270) and p47(271–370) inhibit the binding of
p47full to p97, but p47(1–170) does not. Since p47full
binds to the NH
 
2
 
-terminal domain of p97 (unpublished
data), more detailed mapping of the p47-binding sites in
p97 was performed (Fig. 1 C). The two p47 fragments
showed different binding properties to p97. Although a sin-
gle NH
 
2
 
-terminal domain of p97(1–74) was sufficient for
p47(171–270) binding (Fig. 1 C, top), both p97 NH
 
2
 
-ter-
minal domains, p97(1–74) and p97(134–198), were neces-
sary for p47(271–370) binding (Fig. 1 C, bottom).
To characterize further the binding, EM of negatively
stained complexes of p97/p47 fragments was performed. As
shown in Fig. 1 D, the averaged projection images of the re-
sultant complexes were different to that of p97 alone. Since
the sizes of the p47 fragments are too small (
 
 
 
10 kD) to al-
low direct observation by EM, the observed changes in the
EM images largely represent conformational changes in p97.
These observations therefore suggest that p97 undergoes sig-
nificant conformational changes upon p47 fragment bind-
Figure 1. Two distinct binding interactions in the 
p97/p47 complex. (A) Each GST-tagged deletion 
mutant of p47 was incubated with p97 in a buffer 
containing 0.1% Triton X-100 on ice, then isolated on 
glutathione beads, and bound proteins were fractionated 
by SDS-PAGE. Blots were probed with anti-p97 
antibodies. (B) GST-tagged p97 (1.5  g) was incubated 
with p47full (0.5  g) either alone or in combination 
with a deletion mutant of p47 (4  g) on ice. Blots were 
probed with antibodies to the His-tag on p47 fragments. 
(C) GST-tagged deletion mutants of p97 were incubated 
with each of the p47 fragments containing the p97-
binding sites on ice. Blots were probed with antibodies 
to the His tag on the p47 fragments. (D) p97 was 
preincubated with an excess amount of p47 fragments 
containing the p97-binding sites and purified by gel 
filtration followed by EM observation. 
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ing. In summary, our data show that p47 and p97 have two
distinct binding interactions.
 
Identification of VCIP135 as a p97/p47 
complex–interacting protein
 
We first tried to isolate a p97/p47-interacting protein using
p47full beads but could only isolate p97 (unpublished data).
This suggested that an interacting protein, even if it existed,
might form an unstable ternary complex with p97 and p47.
The existence of two distinct p97/p47 binding interactions
could result in transient or unstable complexes that use only
one p97/p47 binding interaction (Fig. 2 A). Based on the idea
that such unstable p97/p47 complexes could be a target for an
interacting protein X, we next tried to isolate such a protein
using small p47 fragments containing only one of the p97-
binding sites as bait. The p47 fragments were immobilized on
beads, mixed with rat liver cytosol, and bound proteins were
analyzed. The results are shown in Fig. 2 B. As expected, both
p47 fragments bound to p97. Interestingly, another protein of
135kD (VCIP135) was isolated only using p47(171–270)
beads (Fig. 2 B, asterisk). After Zn-staining, this protein band
was excised from the gel and subjected to protein microse-
quencing by electrospray mass spectrometry. We obtained
two partial peptide sequences that allowed us to clone a novel
cDNA sequence corresponding to VCIP135. Its nucleotide
sequence are available from the DNA data bank of Japan data-
base under the accession no. AB045378. Kazusa DNA Re-
search Group also reported the cDNA sequence of its human
homologue (Nagase et al., 2001). Western blotting using anti-
VCIP135 antibodies showed that it was widely expressed all
over the rat tissues (unpublished data).
 
VCIP135 dissociates the p97/p47 complex through 
p97 ATP hydrolysis
 
To characterize the interactions between VCIP135 and the
p97/p47 complex, detailed immunoprecipitation experiments
were performed. As shown in Fig. 3 A, anti-VCIP135 anti-
bodies coimmunoprecipitated a protein of 97 kD from the cy-
tosol (left), which was shown to be p97 by Western blotting
(right middle). However, p47 could not be detected in these
precipitates (Fig. 3 A, right bottom). These data indicate that
VCIP135 can form a stable complex with p97 in cytosol and
that p47 is not part of this complex. As presented in Fig. 3 B,
the fractionation of cytosol by sucrose-gradient sedimentation
showed that VCIP135 distributed in lighter fractions (lanes
3–6) and in the p97-containing fractions (lanes 7–10), sug-
gesting the existence of two populations of cytosolic VCIP135:
one in complex with p97 and the other free of p97.
We then mapped the interaction between VCIP135 and
p97, the results of which are shown in Fig. 3 C (see also
Fig. S1 available at http://www.jcb.org/cgi/content/full/
jcb.200208112/DC1). Various truncated His tag VCIP135
fragments were tested for their ability to bind p97. The
COOH-terminal region of VCIP135 (744–1221) proved to
be important for p97 binding (Fig. 3 C, lane 3). Interest-
ingly, fold recognition analysis of VCIP135 identified a re-
gion between residues 744 and 860 to have a similar fold to
SUMO-1 (Bayer et al., 1998), suggesting a ubiquitin-like
structure for this part of VCIP135. Recently, a nuclear mag-
netic resonance spectroscopy study has shown that the p47
COOH-terminal domain (residues 270–370) is also a ubiq-
uitin-like domain and that this region specifically binds to
the NH
 
2
 
-terminal domain of p97 (Yuan et al., 2001). It is
Figure 2. Identification of VCIP135. (A) A working 
model of how a p97/p47-interacting protein (protein X) 
forms an unstable ternary complex with p97 and p47. 
(B) Purification of VCIP135 from rat liver cytosol. Each 
small p47 fragment with a p97-binding site was 
immobilized on beads and incubated with rat liver 
cytosol. Bound proteins were eluted by a 1 M KCl wash, 
TCA-precipitated, fractionated, and silver stained. 
VCIP135 was isolated on p47(171–270) beads (asterisk). 
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Figure 3. VCIP135 binds to and dissociates the p97/p47 complex. (A) Rat liver cytosol (3.5 mg total protein) was incubated with preimmune 
serum or anti-VCIP135 antibodies. The immunoprecipitates were fractionated by SDS-PAGE followed by staining with Coomassie blue 
(CBB, left) and Western blotting with antibodies to VCIP135, p97, and p47 (WB, right). (B) Rat liver cytosol was size fractionated by 5–30% 
sucrose sedimentation, and the fractions were assayed by Western blotting with antibodies to VCIP135 and p97. (C) His-tagged deletion mutants 
of VCIP135 were incubated with p97 in a buffer containing 0.1% Triton X-100 on ice and then precipitated by anti–His tag antibodies. Blots 
were probed with anti-p97 antibodies. (D) The sequence alignment between VCIP135(744–859) and p47(270–370). Identical (asterisk) and 
conserved residues ( ) are marked. Arrows and black bars show  -strands and  -helices, respectively. The three surface residues identified 
as potential p97-interacting residues in p47 are boxed (Yuan et al., 2001) and are conserved in VCIP135. (E) Rat liver cytosol (3.5 mg total 
protein) was cross-linked with SAND and incubated with preimmune serum or anti-p47 antibodies. The immunoprecipitates were fractionated 
by SDS-PAGE followed by Western blotting with antibodies to VCIP135, p97, p47, and Ufd1p (a negative control). (F) p97 was incubated 
with an excess amount of p47, and the p97/p47 complex was purified using gel filtration in the absence of nucleotides. The purified p97/p47 
complex (1.2  g p97) was incubated in a buffer (50  l) containing 1 mM nucleotide on ice for 30 min. VCIP135 (0.8 or 1.6  g) was added 
into the mixture and incubated on ice for 1 h, and p97 that formed a complex with p47 was coimmunoprecipitated with anti p47 antibodies. 
Blots were probed with antibodies to p97 and p47. 
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therefore plausible that both VCIP135 and p47 use homolo-
gous ubiquitin-like domains (Fig. 3 D) to bind to the same
region of p97, suggesting that p47(271–370) competes with
VCIP135 for p97 binding. This provides a reasonable expla-
nation for our biochemical data that p47(271–370) binds to
p97 but not to the p97/VCIP135 complex (Fig. 2 B).
We originally isolated VCIP135 as a candidate p97/p47-
interacting protein and thus needed to establish whether it
can form a complex with p97/p47. As discussed in the previ-
ous section, a ternary complex of p97/p47/VCIP135 might
be unstable, and hence, we used a cross-linker reagent to cap-
ture it. Coimmunoprecipitation experiments were performed
in the presence of the cross-linker, sulfosuccinimidyl 2-[
 
m
 
-
azio-
 
o
 
-nitrobenzamido]ethyl-1,3
 
 
 
-dithiopropionate (SAND)
(Fig. 3 E). VCIP135 was coimmunoprecipitated by anti-p47
antibodies only in the presence of SAND (Fig. 3 E, lanes 3
and 4) but not in its absence (lane 1). The preimmune serum
did not coimmunoprecipitate any VCIP135 even in the pres-
ence of SAND (Fig. 3 E, lane 5). ufd1p, a negative control,
was not precipitated in any lanes (bottom). Hence, VCIP135
could bind to the p97/p47 complex in cytosol, possibly
forming an unstable complex of p47, p97, and VCIP135
that was captured after chemical cross-linking. This led to the
question of what effect VCIP135 would have on the p97/
p47 complex after forming the unstable ternary complex.
To answer this question, VCIP135 was added to the puri-
fied p97/p47 complex in the presence of nucleotides (Fig. 3
F). After incubation, the p97 bound to p47 was coimmuno-
precipitated by anti-p47 antibodies in order to separate it
from the p97 bound to VCIP135. In the presence of ATP,
VCIP135 dissociated the p97/p47 complex in a dose-depen-
dent manner (Fig. 3 F, left three lanes). In the presence of
AMP–PNP, a nonhydrolyzable ATP analogue, or ADP, the
dissociation of the complex was not observed (Fig. 3 F, the
middle and right three lanes, respectively), indicating that
dissociation of p97/p47 complex by VCIP135 required ATP
hydrolysis. Together these data show that VCIP135 inter-
acts with the p97/p47 complex and dissociates it as a conse-
quence of ATP hydrolysis by p97.
 
VCIP135 dissociates the p97/p47/syntaxin5 complex
 
Although VCIP135 was originally purified from cytosol, it is
also localized to Golgi and ER. As presented in Fig. 4, dou-
ble immunofluorescence staining of VCIP135 and either
 
 
 
1,4-galactosyltransferase (GalT), a Golgi marker, or pro-
tein disulfide isomerase (PDI), an ER marker, showed local-
ization to Golgi and ER.
Syntaxin5 is a SNARE in both the Golgi and ER (Hui et
al., 1997) and has been shown to be involved in the p97/p47
fusion pathway (Rabouille et al., 1998). Hence, we investi-
gated the interaction between VCIP135 and syntaxin5 by
binding experiments using GST-tagged syntaxin5 without
the transmembrane domain (GST–syn5
 
 
 
TM) as shown in
Fig. 5 A. Since syntaxin1 is a SNARE in plasma membranes,
we used GST–syn1
 
 
 
TM as a negative control. We found
that GST–syn5
 
 
 
TM bound VCIP135 very efficiently (Fig.
5 A, lane 1) compared with GST–syn1
 
 
 
TM (lane 2). The
specificity of binding of VCIP135 to syntaxin5 was further
confirmed by the coimmunoprecipitation experiments us-
ing Golgi membranes as shown in Fig. 5 B. 1 M KCl-
washed Golgi membranes were incubated with His-tagged
VCIP135. After removing unbound VCIP135, the mem-
branes were solubilized and VCIP135, and its binding pro-
teins were immunoprecipitated by antibodies to the His tag
on VCIP135. Syntaxin5 was coimmunoprecipitated (Fig. 5
B), providing evidence that VCIP135 binds to syntaxin5 in
Golgi membranes.
We next incubated VCIP135 and GST–syn5
 
 
 
TM to-
gether with p97 and p47 in the absence of nucleotides and
then isolated the proteins bound to GST–syn5
 
 
 
TM (Fig. 5
C). VCIP135 bound to GST–syn5
 
 
 
TM either with p47 or
p97/p47 (Fig. 5 C, lanes 5 and 6, respectively). This sim-
ple binding experiment showed that VCIP135 can form
a quaternary complex with syntaxin5, p97, and p47
(Fig. S2 available at http://www.jcb.org/cgi/content/full/
jcb.200208112/DC1). VCIP135 did not bind to syntaxin5
with p97 (Fig. 5 C, lane 4), a finding which was investigated
further (Fig. 5 F).
A further question is what are the consequences of the ATP
hydrolysis by p97 on the quaternary complex of VCIP135/
p97/p47/syntaxin5? To address this, we first performed
binding experiments: p97/p47 was incubated with either
GST–syn5
 
 
 
TM or VCIP135 
 
  
 
GST–syn5
 
 
 
TM in the
presence of nucleotides, and the proteins bound to GST–
syn5
 
 
 
TM were analyzed (Fig. 5 D; see also Fig. S3 avail-
able at http://www.jcb.org/cgi/content/full/jcb.200208112/
Figure 4. The localization of VCIP135. Double 
immunofluorescence staining of VCIP135 and either 
GalT, a Golgi marker, or PDI, an ER marker, shows 
that VCIP135 localizes to Golgi and ER. NRK cells 
were fixed by methanol at  20 C for 4 min, stained 
with antibodies, and observed by confocal microscopy. 
Bars: (top) 10  m; (bottom) 2  m. 
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Figure 5. VCIP135 binds to syntaxin5 and dissociates the p97/p47/syntaxin5 complex via p97 catalyzed ATP hydrolysis. (A) His-tagged 
VCIP135 (0.4  g) was incubated with either GST, GST–syn5 TM, or GST–syn1 TM (0.5  g each) in a buffer (50  l) containing 0.1% 
deoxycholate on ice and isolated on glutathione beads. Blots were probed with antibodies to VCIP135. (B) 1 M KCl-washed Golgi membranes 
were incubated with His-tagged VCIP135 on ice for 1 h. The membranes were isolated from unbound VCIP135 by centrifugation and 
solubilized in a buffer containing 1% CHAPS. VCIP135 and its interacting proteins were immunoprecipitated by mAbs to the His tag on 
VCIP135 and fractionated by SDS-PAGE followed by Western blotting with antibodies to syntaxin5 peptide, VCIP135, and GS15 (a negative 
control). The bottom band of VCIP135 is a degradative product. (C) GST–syn5 TM (0.5  g) or GST (0.5  g) was incubated with p97 (2  g), 
p47 (1  g), VCIP135 (3  g), or their combinations in 50  l of buffer containing 0.1% deoxycholate, but no nucleotide on ice, and isolated on 
glutathione beads. Blots were probed with antibodies to VCIP135, p97, and p47. (D) GST–syn5 TM (0.5  g) was incubated with VCIP135 
(0.35 or 0.7  g) on ice for 30 min, immobilized on glutathione beads, and washed to remove unbound VCIP135. The nucleotide-free p97/p47 
(2  g p97) was preincubated in buffer containing 1 mM nucleotides on ice for 30 min and added into the beads. After 3-h incubation at 4 C, 
the beads were washed and subjected to Western blotting with antibodies to VCIP135, p97, and p47. (E) p97/p47/GST–syn5 TM-beads and 
VCIP135/p97/p47/GST–syn5 TM-beads were prepared as in C in the presence of 1 mM AMP–PNP. Then, the beads were washed with buffer 
containing 5 mM AMP–PNP or ATP and incubated at 4 C for 3 h. (F) VCIP135/GST–syn5 TM beads were prepared as in C. p97 was added 
into the mixture and incubated at 4 C for 3 h. Blots were probed with antibodies to VCIP135. (G) VCIP135 (1 or 2  g) and  -SNAP (0.1  g) 
were incubated with GST–syn5 TM (0.4  g) or GST (0.4  g) on ice for 1 h and then isolated on glutathione beads. Blots were probed with 
antibodies to VCIP135 and  -SNAP. See also Figs. S3 and S4 available at http://www.jcb.org/cgi/content/full/jcb.200208112/DC1. 
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DC1). In the presence of ATP, the addition of VCIP135
prevented p97 and p47 from binding to syntaxin5 and
VCIP135 itself only bound poorly to syntaxin5 (Fig. 5 D,
left three lanes). However, in the presence of AMP–PNP or
ADP, p97 and p47 bound to syntaxin5 even when VCIP135
was added, and VCIP135 also bound to syntaxin5 (Fig. 5 D,
right six lanes). These data suggest that both VCIP135 and
the p97/p47 complex bind to syntaxin5, resulting in the for-
mation of a transient quaternary complex that could be disso-
ciated through p97 ATP hydrolysis. To clarify this further,
we performed dissociation experiments as described in Fig. 5
E (see also Fig. S4 available at http://www.jcb.org/cgi/
content/full/jcb.200208112/DC1). We initially prepared com-
plexes of p97/p47/GST–syn5
 
 
 
TM or VCIP135/p97/p47/
GST–syn5
 
 
 
TM in the presence of AMP–PNP. Both com-
plexes were maintained under these conditions. Then, the
beads containing both complexes were incubated in the pres-
ence of AMP–PNP or ATP. The p97/p47/GST–syn5
 
 
 
TM
complex was maintained intact even in the presence of ATP
(Fig. 5 E, lanes 1 and 2). However, the VCIP135/p97/p47/
GST–syn5
 
 
 
TM complex was dissociated only in the pres-
ence of ATP (Fig. 5 E, lane 4), and the VCIP135/p97 com-
plex was observed in the supernatant (unpublished data).
This result strongly suggests that VCIP135 dissociates the
p97/p47/syntaxin5 complex via ATP hydrolysis by p97.
Although VCIP135 can bind to p97 in cytosol (Fig. 3 A),
VCIP135 bound to syntaxin5 does not form a complex with
 
p97 (Fig. 5 C, lane 4). This suggests that the formation of a
VCIP135/p97 complex on syntaxin5 dissociates VCIP135
from syntaxin5. To investigate this, we performed stripping
experiments as shown in Fig. 5 F. p97 was added to a
complex of VCIP135/GST–syn5
 
 
 
TM, and the remaining
amounts of VCIP135 on GST–syn5
 
 
 
TM were determined.
The addition of p97 decreased the amount of VCIP135
bound to syntaxin5 (Fig. 5 F). The dissociated VCIP135
was observed as a complex with p97 in the supernatant (un-
published data).
We also investigated whether VCIP135 has any effect on
the binding of 
 
 
 
-SNAP to syntaxin5. As shown in Fig. 5 G,
VCIP135 partially prevented 
 
 
 
-SNAP binding to GST–
syn5
 
 
 
TM, suggesting that VCIP135 directs syntaxin5 to
p97/p47 but not to 
 
 
 
-SNAP/NSF.
 
VCIP135 is essential for p97/p47-mediated 
membrane fusion
 
We have shown that VCIP135 binds to syntaxin5 and disas-
sembles the p97/p47/syntaxin5 complex through p97 ATP
hydrolysis. Next, we wanted to ascertain whether VCIP135
contributes to p97/p47-mediated membrane fusion using an
in vitro Golgi reassembly assay. As shown in Fig. 6 A, cister-
nal regrowth was observed by the incubation of mitotic
Golgi fragments with the p97/p47 complex (the control).
Anti-VCIP135 antibodies inhibited the p97/p47-mediated
cisternal regrowth by 
 
 
 
75% compared with the control.
Figure 6. VCIP135 is essential for 
p97/p47-mediated membrane fusion. 
(A) Mitotic Golgi membranes were 
incubated with the indicated components 
at 37 C for 60 min. The membranes 
were fixed, processed, and the percentage 
of membrane in cisterna was determined. 
An antibody to VCIP135 was added 
together with the p97/p47 complex (50  g 
p97/ml) to mitotic Golgi membranes. 
The same antibody was quenched 
by a VCIP135 fragment and added. 
Mean   SD (n   4); 0% represents the 
buffer (21.2% in cisternal membranes) 
and 100% represents p97/p47 alone 
(41.8% in cisternal membranes). 
(B) Antibodies to VCIP135 were added 
to mitotic Golgi membranes together 
with the components of the NSF pathway: 
NSF (100  g/ml),  -SNAP (25  g/ml), 
and  -SNAP (25  g/ml), p115 (8  g/ml). 
Mean   SD (n   3); 0% represents the 
buffer (22.5% in cisternal membranes) 
and 100% represents NSF/SNAPs/p115 
alone (40.4% in cisternal membranes). 
(C) The top panels show the amounts of 
VCIP135 in mitotic Golgi membranes 
and 1 M KCl-washed membranes. 1 M 
KCl-washed or nonwashed mitotic Golgi 
membranes were incubated with several 
components or their combinations; 
p97/p47 (50  g p97/ml), VCIP135 
(15  g/ml), p97 (50  g/ml). Mean   SD 
(n   4); 0% represents the buffer (23.2% in cisternal membranes) and 100% represents non salt-washed membranes with p97/p47 alone 
(43.4% in cisternal membranes). (D) 1 M KCl-washed mitotic Golgi membranes were incubated with p97/p47 (50  g p97/ml) and several 
doses of VCIP135. Results are the averaged percentage (n   3); 0% represents VCIP135/p97   0 (21.2% in cisternal membranes) and 100% 
represents VCIP135/p97   1/4 (44.1% in cisternal membranes).862 The Journal of Cell Biology | Volume 159, Number 5, 2002
This inhibition was rescued by quenching the antibodies
with a VCIP135 fragment. The antibodies had no effect on
NSF-mediated cisternal regrowth (Fig. 6 B). Together, these
results strongly suggest that VCIP135 is specifically involved
in the p97/p47 membrane fusion pathway.
The above assays were performed with Golgi mitotic
fragments that were contaminated by membrane-bound
VCIP135. Therefore, we performed assays using VCIP135-
free membranes obtained by 1 M KCl washes (Fig. 6 C,
top). When the VCIP135-free membranes were incubated
with p97/p47, VCIP135, or p97/VCIP135, no cisternal re-
growth was observed. Only when p97/p47 and VCIP135
were added together was cisternal regrowth observed (Fig. 6
C). Thus, VCIP135 is an essential factor for p97/p47-medi-
Figure 7. VCIP135 is required for 
Golgi assembly in vivo. (A) NRK cells at 
prophase (or early prometaphase) were 
injected with antibodies and fixed after 
they exited mitosis. Golgi (green, top), 
injected antibodies (red, top), and 
chromatin (bottom) were stained by 
monoclonal anti-GalT antibodies, 
anti–rabbit IgG antibodies, and 
Hoechst33342, respectively. Bars, 10  m. 
(B) Representative EM images of Golgi in 
daughter cells after antibodies or 
quenched antibodies were microinjected. 
Bars, 0.5  m. (C) Immunolabeling EM 
images of Golgi area in the NRK cells 
microinjected with anti-VCIP135 
antibodies. For immunolabeling of 
Golgi marker proteins, monoclonal 
antibodies to either GalT (left) or GM130 
(right) were used. Arrows show immuno-
labeled vesicles and tubules. Bars, 0.5  m. 
(D) Golgi membranes were classified and 
counted as described previously (Shorter 
and Warren, 1999; Seemann et al., 2000) 
in microinjected cells. Mean   SD 
(n   7–9). VCIP135 is essential for p97-mediated fusion | Uchiyama et al. 863
ated membrane fusion. Fig. 6 D shows the dose dependency
of VCIP135 on cisternal regrowth. Interestingly, it is bipha-
sic: a low level of VCIP135 (1/8–1/2 [mol/mol p97]) had a
positive effect on the cisternal regrowth, whereas a higher
level of VCIP135 had a negative effect.
VCIP135 is required for Golgi and ER assembly in vivo
Although many groups have reported the in vitro function
of p97 in the biogenesis of organelles, its in vivo function
still remains unclear. Since p97 is known to be involved
in several biological processes (Patel and Latterich, 1998;
Meyer et al., 2000; Dai and Li, 2001; Ye et al., 2001;
Jarosch et al., 2002), a specific cofactor other than p97
would be a better target to mediate its fusion-specific func-
tion. We have now identified VCIP135 as an essential cofac-
tor for the fusion activity of p97 in vitro. To study the func-
tion of VCIP135 in vivo, we microinjected anti-VCIP135
antibodies into cells and investigated its effects on the reas-
sembly of organelles at the end of mitosis. Cells at prophase
(or early prometaphase) were injected with anti-VCIP135
antibodies and fixed after they entered interphase. An anti-
VCIP135 antibody quenched by its antigen and rabbit ran-
dom IgG were injected as negative controls, and an anti-p47
antibody was used as a positive control. The injections of
these antibodies had no effect on cell cycle progression.
As shown in Fig. 7 A, the Golgi was stained by mAbs to
GalT, a Golgi marker (Rabouille et al., 1995a). Hoechst
DNA staining showed that injected cells had exited mitosis
(bottom). After the injection of either anti-VCIP135 or
anti-p47 antibodies, Golgi still localized to a perinuclear re-
gion in daughter cells (top panel 2 and 4, respectively). The
ultrastructure of the Golgi in injected cells was investigated
by EM (Fig. 7, B–D). In anti-VCIP135 antibody-injected
cells, highly organized Golgi complexes were lost: stacked
cisternae were rarely observed (anti-VCIP135 antibody in-
jection, 30.3% of cisternal membranes in stacks; random
IgG injection, 80.4%), and the number of tubular/fenes-
trated structures was greatly increased (Fig. 7 B, top left). As
shown in Fig. 7 C, immuno-EM images using antibodies to
Golgi marker proteins, GalT or GM130 (Nakamura et al.,
1995; Rabouille et al., 1995a), showed that these frag-
mented membranes were derived from Golgi. The quantita-
tive results are shown in Fig. 7 D. The injection of anti-
VCIP135 antibodies significantly decreased the percentage
of cisternae per Golgi area by a half and significantly in-
creased the percentage of tubules twofold compared with in-
jections of quenched antibodies and random IgG. The
amount of vesicles was not changed. Similar morphological
changes were observed after the injection of anti-p47 anti-
bodies (Fig. 7 B, left bottom, and D). Since the injection of
the anti-VCIP135 antibodies at the same concentration into
interphase cells caused no obvious changes in the organiza-
tion of the Golgi apparatus (by IF and EM observation [un-
published data]), these morphological changes were most
likely caused by the inhibition of reassembly at the end of
mitosis. These data show that VCIP135 functions in the re-
assembly of highly organized Golgi structures in living cells
as does p47, indicating that p97-mediated fusion is required
for Golgi reassembly in living cells.
p97/p47 has also been implicated in ER membrane fusion
in an in vitro system (Hetzer et al., 2001). VCIP135 local-
izes to ER membranes and Golgi (Fig. 4, bottom). Hence,
we investigated the effect of antibodies to VCIP135 on ER
structures. As shown in Fig. 8 A, the injection of anti-
VCIP135 antibodies caused formation of a large meshed ER
network in daughter cells (panel 2). Injection of anti-p47
antibodies had a similar effect (Fig. 8 A, panel 4). This
change in ER structure was not observed after injecting
quenching antibodies (Fig. 8 A, panel 3) or random IgG
(panel 1). To quantify the degree of ER network formation,
the number of three-way junctions was counted using con-
focal microscopy (Fig. 8 B). The number of three-way junc-
tions was significantly decreased by  70% compared with
control by the injection of antibodies to VCIP135 and p47.
These data indicate that the p97/p47/VCIP135 pathway
also participates in ER network formation in living cells.
The structures of other organelles, including nuclear enve-
lope, mitochondria, and lysosome, were also investigated by
Figure 8. VCIP135 is required for ER 
network formation in vivo. (A) Antibodies 
were microinjected into CHO cells 
expressing GFP-tagged HSP47. Since ER 
structures were easily damaged and lost 
after fixation, they were observed in 
living cells without fixation by confocal 
microscopy. Representative images of 
ER in daughter cells after the injection 
of antibodies are shown. N, nucleus. 
Bars, 5  m. (B) The number of three-
way junctions was counted by confocal 
microscopy as a parameter of ER network 
formation. Mean   SD (n   9).864 The Journal of Cell Biology | Volume 159, Number 5, 2002
EM in the antibodies injected cells. After microinjection of
either anti-VCIP135 or anti-p47 antibodies, no obvious
morphological changes in these organelles were observed
(unpublished data) in contrast with the changes seen in the
structures of the Golgi and ER. Detailed images of the cells
injected with anti-VCIP135 antibodies are shown in Figs.
S5 and S6, available at http://www.jcb.org/cgi/content/full/
jcb.200208112/DC1.
Discussion
The p97/p47 membrane fusion pathway differs from the
NSF/SNAPs pathway in that p97 catalyzed ATP hydrolysis
does not dissociate the p97/p47/SNARE complex. To ex-
plain these apparent functional differences, we developed a
model for p97/p47 action that would require another factor
to dissociate the p97/p47/SNARE complex, presumably as
part of the SNARE priming process. We postulated that this
factor would interact with the p97/p47 complex and tried to
isolate it. We first found two distinct binding interactions
for the p97/p47 complex and based on this mapping infor-
mation identified a novel protein VCIP135 from cytosol.
VCIP135 dissociates the p97/p47/syntaxin5 complex via
p97 catalyzed ATP hydrolysis and is shown to be essential
for p97/p47-mediated membrane fusion.
In cytosol, we have shown that VCIP135 dissociates p97
from a p97/p47 complex by forming a complex with p97:
p97 is translocated from p47 to VCIP135 through p97
ATP hydrolysis (Fig. 3). We would predict a similar situa-
tion for p97/p47 bound to syntaxin5, where VCIP135
would dissociate p97 from a p97/p47/syntaxin5 complex.
VCIP135 bound to syntaxin5 is thought to associate with a
syntaxin5-bound p97/p47 complex with syntaxin5 acting
as a scaffold for the p97/p47 dissociation reaction. Hence,
we present our model to explain how VCIP135 dissociates
the p97/p47/syntaxin5 complex. First, VCIP135 interacts
with the p97/p47 complex on syntaxin5. p97-catalyzed
ATP hydrolysis causes the translocation of p97 from p47
to VCIP135, resulting in a metastable complex of p97/
VCIP135/syntaxin5. Since the p97/VCIP135/syntaxin5
complex is very unstable (Fig. 5 C), a tighter VCIP135/p97
complex then dissociates from syntaxin5 (Fig. 5 F). During
this disassembly process, p47 is also dissociated from
syntaxin5 (Fig. 5, D and E). p47 can bind to syntaxin5
when dissociated from p97 and present alone (Rabouille et
al., 1998). VCIP135 cannot interact with p47 directly (Fig.
3 A). Hence, it is most likely that a conformational change
in syntaxin5 was caused to lessen its binding affinity for
p47 during this disassembly process. We have found that
p97 mutants that lacked ATPase activities show no mem-
brane fusion activities in the in vitro Golgi reassembly assay
(unpublished data), indicating that p97-mediated fusion
requires its ATPase activity: i.e., p97 is thought to function
for the ATPase-dependent disassembly of SNAREs. Con-
sidering that the disassembly of the p97/p47/SNARE com-
plex by VCIP135 requires ATP hydrolysis (Fig. 5 E), we
suggest that the function of VCIP135 in membrane fusion
is to mediate the dissociation of the p97/p47/SNARE com-
plex, which may be part of the SNARE priming process.
Recently, NSF/SNAP have been suggested to mediate the
ATPase-independent SNARE assembly and the ATPase-
dependent SNARE disassembly (Müller et al., 2002). It is
unclear at this moment whether p97/p47/VCIP135 also
have ATPase-independent functions or not. Nevertheless,
further biochemical and functional investigations are nec-
essary to clarify the mechanism and functional significance
of the disassembly of the p97/p47/SNARE complex medi-
ated by VCIP135.
The binding of VCIP135 to syntaxin5 independently of
p47 (Fig. 5 C) allows VCIP135 to be closely associated with
the p97/p47 complex, whereas in cytosol such an asso-
ciation is less likely. Accordingly, a smaller amount of
VCIP135 (1/8–1/4 [mol/mol p97]) was sufficient for the
disassembly of the p97/p47/syntaxin5 complex (Fig. 5 D),
whereas a larger amount of VCIP135 (1/2–1 [mol/mol
p97]) was necessary for the dissociation of the p97/p47
complex (Fig. 3 D). The disassembly of the p97/p47/
SNARE complex works positively for membrane fusion,
and the dissociation of the p97/p47 complex works nega-
tively. This may provide a mechanism to explain the bipha-
sic dose-dependent curve of VCIP135 in Golgi cisternal re-
growth (Fig. 6 D). On the other hand, p47 has been
reported to inhibit p97 ATPase activity (Meyer et al.,
1998). One possible explanation for this inhibition is that
p47 interacts with p97 using two distinct binding interfaces
(Fig. 1) to form a tight conformationally restrictive complex
that inhibits p97 ATPase activity. The inhibition of p97
ATPase activity can be reduced if both p47-binding sites are
not occupied, and the metastable complex of VCIP135/
p97/p47 would represent such a case: VCIP135 interacts
with the p97/p47 complex that uses only one p47-binding
site. The release of ATPase inhibition in this transient com-
plex could allow the necessary ATPase activity required for
p97 translocation from p47 to VCIP135.
Finally, we have clarified by microinjection of antibodies
to VCIP135 and p47 that fusion-specific cofactors of p97
participate in Golgi and ER assembly (Figs. 7 and 8). This is
the first report to show p97-mediated membrane fusion in
vivo. From experiments using an in vitro Golgi reassembly
assay, it is suggested that p97 may mediate homotypic fusion
of short tubules and larger vesicles to form unfenestrated cis-
ternae in contrast to NSF-mediating heterotypic fusion of
small vesicles (Acharya et al., 1995; Rabouille et al., 1995b).
Our results are in good agreement with this. As shown in
Fig. 7 D, the injection of anti-VCIP135/p47 antibodies
caused accumulation of tubules, which are thought to be the
starting membranes for homotypic fusion, but not vesicles,
which are required for heterotypic fusion. Unfenestrated cis-
ternae, products of homotypic fusion, were decreased by in-
jection of anti-VCIP135/p47 antibodies (Fig. 7, B and D).
These in vivo data strongly support the hypothesis that p97
mediates homotypic fusion. Moreover, the injection of anti-
VCIP135/p47 antibodies inhibited stack formation as well
as cisternal regrowth (Fig. 7 B), which is consistent with the
previous observation in semiintact cells (Acharya et al.,
1995). One possible explanation is that stack formation may
require growth of unfenestrated cisternae mediated by p97:
the extended and smooth surfaces of cisternae could give
each individual cisterna more opportunities to meet another
one for stacking. VCIP135 is essential for p97-mediated fusion | Uchiyama et al. 865
In this paper, we report that, similar to NSF/SNAPs, p97/
p47 is dissociated from the SNARE through p97-mediated
ATP hydrolysis. The dissociation of p97/p47 from the
SNARE differs from that of NSF/SNAP in that p97/p47 re-
quires the assistance of another essential factor, VCIP135.
We are now focusing on whether p97, p47, and VCIP135
are necessary and sufficient for the priming of SNAREs and
determining the underlying mechanism.
Materials and methods
Proteins and antibodies
NSF, SNAPs, p47, and GST–syn5 TM were prepared as described previ-
ously (Rabouille et al., 1995b, 1998; Kondo et al., 1997). p115 and p97
were purified from rat liver cytosol (Rabouille et al., 1995b; Kondo et al.,
1997). Rat p97 cDNA was PCR amplified from a rat liver cDNA library and
subcloned into pTrcHisB. To obtain GST-tagged and His-tagged deletion
mutants of p97 and p47, the corresponding cDNAs with stop codons were
subcloned into pGEX4T-2 and pQE30, respectively. mAbs to PDI and GalT
were gifts from Dr. Vaux (Oxford University, Oxford, UK) and Dr. Su-
ganuma (Miyazaki Medical College, Miyazaki, Japan), respectively. Mono-
clonal antibodies to p97, His tag, and GM130 were purchased from Pro-
gen, QIAGEN, and BD Transduction, respectively.
Purification of VCIP135
His-p47(171–270) and His-p47(271–370) (100  g each) were biotinylated
using EZ-Link Sulfo-NHS-LC-biotin (Pierce Chemical Co.), bound to im-
mobilized NeutrAvidin plus beads (Pierce Chemical Co.), and washed
with 1 M KCl in buffer A (20 mM Hepes, 1 mM MgCl2, 1 mM ATP, 1 mM
DTT, 0.1% Triton X-100, 10% glycerol, pH 7.4). Rat liver cytosol (65 mg
total protein), which was supplied with KCl (to 1 M) and Triton X-100 (to
0.1%), was incubated with the resulting beads for 1 h at 4 C. The mixtures
were diluted to 0.15 M KCl with buffer A and incubated for 2 h at 4 C. The
binding proteins were eluted with 1 M KCl in buffer A, subjected to trichlo-
roacetic acid precipitation, and separated by SDS-PAGE.
Cloning of VCIP135 cDNA
The Zn-stained protein band was excised from the gel and subjected to
protein microsequencing as described previously (Meyer et al., 2000).
From the protein microsequencing, we obtained two partial peptide se-
quences: peptide 1, QL(I)DPDVVEAQR and peptide 2, QEEL(I)AVTGK.
An EST database search showed one rat cDNA clone (EST236550) that
contained a corresponding cDNA sequence to peptide 1. An identical
clone was isolated by PCR from a rat liver cDNA library. Pfu Turbo
(Stratagene) was used as DNA polymerase. This clone was sequenced to
confirm that it encoded peptide 1. Since this clone had a stop codon in
the reading frame, its cDNA sequence was extended to the 5 -end with a
Marathon cDNA Amplification kit (CLONTECH Laboratories, Inc.) (gene
specific primer, 5 -TGATGCCTGAATAGAAGAAACCATTTCCTGC-3 
and nested primer, 5 -CTCAACCACATCGGGATCAATCTGCCTACC-3 ).
We obtained four independent clones of  2.3 kbp and determined their
sequences. The sequences of all the clones were identical, and they en-
coded peptide 2. The second 5 -RACE was performed to extend further
to the 5 -end (gene-specific primer, 5 -CTCCACGCAATACAGATTG-
GCTTGTTC-3   and  nested primer, 5 -AAATGACCATCTCTCCCAGTG-
CAC-3 ). Three independent clones of 1.1–1.05 kbp covered the 5 -end,
and all had identical sequences. Finally, the entire cDNA of 3,804 bp
was reisolated directly from rat liver cDNA library by PCR and rese-
quenced. Its start codon was confirmed using an in vitro transcription/
translation system (Promega).
After mutating the BamHI sites in the ORF of VCIP135 without chang-
ing the encoded amino acid sequence, it was subcloned into pTrcHisB
using BamHI and EcoRI sites. Recombinant VCIP135 was expressed in
Escherichia coli and purified with Ni beads followed by further purifica-
tion with gel filtration and 5–30% sucrose-gradient sedimentation. His-
tagged VCIP135(744–1221) was used to raise rabbit anti-VCIP135 poly-
clonal antibodies.
Binding experiments with purified proteins
Binding experiments with GST–syn5 TM were performed using buffer A
containing 0.15 M KCl, 0.5 mg/ml trypsin inhibitor, and 0.1% deoxycholic
acid instead of 0.1% Triton X-100. For all other binding experiments, 0.1%
Triton X-100 was used. GST-tagged proteins and their interacting partners
were precipitated by glutathione-Sepharose. His-tagged proteins were pre-
cipitated using anti-His antibodies and protein A–Sepharose.
Sucrose-gradient sedimentation
Rat liver cytosol was loaded onto a 5–30% sucrose gradient (containing
0.1 M KCl, 20 mM Hepes, 1 mM MgCl2, 1 mM ATP and 1 mM DTT, pH
7.4) and centrifuged for 5 h at 55,000 rpm in a TLS-55 rotor (Beckman
Coulter). 12 fractions were collected from the top.
Immunoprecipitation from rat liver cytosol
Rat liver cytosol (3.5 mg total protein) was mixed with anti-VCIP135 anti-
bodies in buffer A containing 0.15 M KCl. VCIP135 and its binding pro-
teins were immunoprecipitated by protein A beads. Preimmune serum was
used as a control.
For the immunoprecipitation experiment using anti-p47 antibodies, a
cross-linker reagent, SAND (Pierce Chemical Co.), was added to rat liver
cytosol (pH 7.4) and photoactivated by a 5 min exposure to UV light (365
nm). The cross-linking reaction was quenched by the addition of Tris (pH
7.4) to 0.1 M, and the cytosol was then subjected to immunoprecipitation
by anti-p47 antibodies.
Immunoprecipitation from membranes
Golgi membranes were purified from rat liver (Hui et al., 1998). 1 M KCl-
washed membranes (150  g) were incubated with His-tagged VCIP135 (2  g)
in buffer (40 mM Hepes, 0.15 M KCl, 1 mM MgCl2, 0.2 M sucrose, pH 7.4) for
1 h at 4 C. The membranes were recovered by centrifugation and solubilized
in buffer (40 mM Hepes, 0.15 M KCl, 1 mM MgCl2, 1 mM DTT, 10% glycerol,
1% CHAPS, protease inhibitor cocktail [Roche], pH 7.4). Monoclonal anti-His
antibodies were added together with anti–mouse IgG-conjugated Dynabeads
(Dynal). After incubated for 3 h at 4 C, the beads were washed and subjected
to Western blotting with anti–syntaxin5 peptide antibodies.
Negative staining
Negative staining was performed as described previously (Kondo et al.,
1997). 550 individual images of the end-on–oriented complexes were av-
eraged and sixfold rotationally symmetrized.
In vitro Golgi reassembly assay
The in vitro Golgi reassembly assay was performed as reported previously
(Shorter and Warren, 1999). For the preparation of salt-washed membranes,
KCl was added into the mixture to 1 M, incubated on ice for 30 min, and
the membranes were recovered by centrifugation. All components added in
this assay were prepared as recombinant proteins from E. coli.
Microinjection of antibodies into living cells
Affinity-purified antibodies ( 8  g/ l) were microinjected into prophase (or
early prometaphase) NRK cells. The cells were fixed 1.5 h after injection
and stained to allow visualization of the Golgi complex. For observation of
ER structure, we used a stable cell line expressing GFP-tagged HSP47, an ER
protein (Nagata, 1998), whose localization to ER was confirmed by immu-
nofluorescence staining using anti-PDI antibodies. ER structures were ob-
served in living cells, without fixation, using confocal microscopy.
For EM study, NRK cells were roughly synchronized. Cells were cultured
for 12 h in presence of aphidicolin (2.5 mg/l). After washing out aphidi-
colin, they were cultured for 6 h and microinjected. Cells were grown on a
coverslip on which a square area of  1 mm   1 mm was outlined by a di-
amond pen. All prophase (or early prometaphase) cells within the area
were injected; all injections were done within 5–10 min. Uninjected cells
within the area were completely removed by an injection needle. Fluores-
cence of coinjected Cy3–BSA ( 1  g/ l) was used as an indicator to distin-
guish injected cells from uninjected cells. The cells were fixed 1.5 h after
injection. Before fixation, undivided cells within the area were completely
removed by an injection needle. After fixation and embedding into Epon,
the cells within the area were ultrathin sectioned (Seemann et al., 2000).
The Golgi area was defined by the boundary enclosing the Golgi stacks, tu-
bules, and tubulo-reticular networks, and all the vesicles that were within
100 nm of these membranes. Membrane profiles in the Golgi area were di-
vided into three categories: cisternae, tubules, and vesicles, and the relative
proportion of each category of membranes was counted using an intersec-
tion method as described previously (Shorter and Warren, 1999).
Immuno-EM
For immunolabeling, cells were fixed with PLP fixative (2% formaldehyde,
0.01 M periodatem, 0.075 M lysine–HCl in 0.075 M phosphate buffer, pH
7.4) for 2 h at RT. Cells were permeabilized with 0.01% saponin (Sigma-866 The Journal of Cell Biology | Volume 159, Number 5, 2002
Aldrich) and immunolabeled using anti-GalT or anti-GM130 mAbs and 1.4 nm
gold particle–conjugated Fab’-fragments against mouse IgM   IgG (Nano-
probes). Nanogold was silver enhanced using HQ Silver kit (Nanoprobes) for
0.5 to 4 min and gold toned with 0.05% gold chloride (Arai et al., 1992). Af-
ter washing, the cells were processed for epon embedding as above.
Online supplemental material
Online supplemental figures are available at http://www.jcb.org/cgi/
content/full/jcb.200208112/DC1. Fig. S1 shows the mapping data on a
VCP135-binding region in p97. Fig. S2 presents the immunoprecipitation
results indicating the p47/syntaxin5/VCIP135 complex. The quantitation
results of Fig. 5, D and E, are shown in Figs. S3 and S4, respectively. Figs.
S5 and S6 show the detailed images of the cells injected with anti-
VCIP135 antibodies.
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